Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis

Abstract

Objective: Ulcerative colitis (UC), one of the most stubborn diseases, is mainly treated by aminosalicylic acid (ASA). However, the side effects of ASA include vomiting, nausea, rash, diarrhea, headache, etc, which seriously affect life-quality of UC patients. Probiotics such as bifid triple viable (BTV) could reduce drug-induced adverse reactions and has a good clinical effect on UC. Therefore, we aimed to evaluate the clinical efficacy and safety of BTV plus ASA in treating UC. Methods: PubMed, Cochrane Library, Embase, Chinese Biomedical Literature Database, Chinese Scientific Journal Database, Chinese National Knowledge Infrastructure, and Wanfang databases were searched from the inception dates to October 12, 2018. Randomized controlled trials (RCTs) were included by comparing BTV plus ASA programs with ASA alone in patients with UC. Methodological quality was assessed by 2 independent researchers according to the inclusion criteria and exclusion criteria. Meta-analysis was performed by using the Review Manager 5.3 Software. Risk ratios (RRs), 95% confidence interval (CI), and standardized mean difference were calculated. Results: Sixty RCTs involving 4954 participants were selected for final review. Compared with ASA, BTV plus ASA significantly improved the clinical effect rate [RR = 1.23, 95% CI (1.20, 1.26), P < .00001]; reduced the relapse rate [RR = 0.34, 95% CI (0.18, 0.62), P = .0005]; and adverse effect rate [RR = 0.66, 95% CI (0.53, 0.82), P = .0002]. Compared with the controls, levels of tumor necrosis factor-α, interleukin-6 (IL-6), IL-8, C-reactive protein (CRP), hypersensitive CRP, erythrocyte sedimentation rate, and malondialdehyde were reduced; levels of IL-10, CD3+, CD4+, and superoxide dismutase were increased in BTV plus ASA group. Conclusions: BTV plus ASA has positive therapeutic effects on UC, and it might be a safe way to treat UC. However, comprehensive clinical trials are needed to obtain high level of clinical evidence.

Capsaicin combined with dietary fiber prevents high‐fat diet associated aberrant lipid metabolism by improving the structure of intestinal flora

“…Moreover, CAP improved insulin effectiveness and increased SCFAs and the abundance of bacterial strains, for example, the Akkermansia genus, mitigating high‐fat diet‐induced metabolic abnormalities (Hui et al, 2019 ; Rosca et al, 2020 ; Shen et al, 2017 ). Simultaneously, CAP increased the gut plentifulness of Desulfovibrio genus bacteria, which promotes colitis development (Chen et al, 2019 ). Therefore, we resolved to investigate whether combining CAP with other natural ingredients in the diet might: (1) improve glucose and lipid metabolism; and (2) decrease the abundance of pathogenic bacteria further than did CAP alone.…”

Influences of Bifid Triple Viable Capsules Plus Cetirizine on Gut Microbiota and Immune Function in Children with Eczema

“…However, a pharmacological study reported that in the model of enteritis in mice, oral administration of bifid triple viable capsules can reduce intestinal inflammation and down-regulate pro-IFs. 15,16 Therefore, combined with the results of this study, the IFs of children treated with the combination of the two drugs will be better improved.…”

“…14 Another drug, bifid triple viable capsules, is composed of Bifidobacterium, Lactobacillus and Enterococcus, which has been shown to be effective against diarrhea caused by GMB disturbances or enteritis and has been approved by the State Food and Drug Administration of China as a nonprescription drug. 15 Pharmacological studies have shown that bifid triple viable, given orally, can alleviate intestinal inflammations via regulating beneficial and harmful flora like Lactobacillus and Escherichia coli. [16][17][18] However, there is a shortage of research on the role of the two drugs in infantile eczema (IE).…”

Enteral Nutrition Supplemented with Transforming Growth Factor-β, Colostrum, Probiotics, and Other Nutritional Compounds in the Treatment of Patients with Inflammatory Bowel Disease

“…There were six metanalyses published during the last two years [13,[69][70][71][72][73], the results of which are summarized in Table 4. The conclusions that we can draw from these metaanalyses could be the following: The administration of probiotics either alone or in combination with mesalazine could increase the rate of clinical remission of patients with UC.…”